Pancreas Cancer Discussion Page:
An Unmoderated Forum
*
 
Support pancreas research*DISCLAIMER: This page is an unmoderated forum, and the opinions expressed herein do not necessarily reflect the viewpoint of The Johns Hopkins Medical Institutions. Patients are advised to consult their personal physicians before making any medical decisions.
FULL DISCLAIMER

Pancreas Cancer

SuperGen Stock Drops was posted 08/31/2000 02:17 pm by Suzy-I
E-mail Address:

Message Text
Problems with clinical trials with Rubitecan has caused SuperGen's stock to drop. See below:

SuperGen shares tumble on talk of cancer drug delay

LOS ANGELES, Aug 31 (Reuters) - Shares of SuperGen Inc. fell more than 20 percent on Thursday after a Wall Street analyst said the pharmaceutical company's launch of a new pancreatic cancer drug was likely to be delayed.

Shares of the San Ramon, Calif. company dropped $6-11/16 to $21 in afternoon trading on the Nasdaq. The stock has a 52-week high of 77-5/16 and a low of 19.

Prudential Securities analyst Peter Drake on Thursday cut his investment rating on SuperGen to hold from strong buy, citing organisational problems with clinical trials of the company's late-stage cancer drug Rubitecan.

``We are downgrading SuperGen...based on growing concerns over the clinical progress of lead compound Rubitecan, the company's oral anti-tumour candidate for pancreatic cancer and the primary force behind our valuation of SuperGen shares,'' Drake said in a report.

Previously, the outlook for SuperGen assumed fourth quarter 2000 completion of an advanced trial of the drug, filing for marketing approval by first or second quarter 2001, and approval in the second half of 2001, but it now seems that the drug will not be launched until late 2002, the analyst said.

Officials at SuperGen could not be reached for comment.

The Prudential analyst attributed the expected delay to ``significant issues in managing'' the 1,800-patient multicenter trial, including problems with keeping patients within the trial parameters.

He added that SuperGen management has indicated that as many as 10-15 percent of the patients are currently ineligible for study inclusion due to protocol violations.

``Adding to this general uncertainty, we understand from industry contacts that partner Abbott Laboratories is concerned over the progress of the trial. SUPG management confirmed this with us yesterday,'' Drake said.

Reply to this message | Return to Main Message List


Responses

*DISCLAIMER: This page is an unmoderated forum, and the opinions expressed herein do not necessarily reflect the viewpoint of The Johns Hopkins Medical Institutions. Patients are advised to consult their personal physicians before making any medical decisions.
FULL DISCLAIMER


Pancreas Home | Surgical | Medical | Basic Sci | Docs | Registry | FAQ | Appts | Chat

Feedback | Pathology Home | Oncology Center Home | Search
Copyright © 2020 The Johns Hopkins University, Baltimore, Maryland
Last Modified: 11/11/2002 10:50 am